Phase 3Active, not recruiting

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection

Sponsor
Gilead Sciences (Industry)
Enrollment
90 enrolled
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF; TDF Placebo
Ages
children
Registry
NCT01651403, CTIS2024-517526-26-00, EUCTR2012-000586-20

Full record on ClinicalTrials.gov

From the registry

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

Primary outcomes

  • Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
  • Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)

History

  1. Study completion expected

  2. Last registry update

  3. Results first posted

  4. Primary completion

  5. Started

  6. Registered